Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hubei Duorui Pharmaceutical Co., Ltd. is a Chinese pharmaceutical manufacturing company founded in 2005 and based in Jingzhou, Hubei Province. The company specializes in the research, development, and large-scale production of therapeutic infusions, small molecule formulations, and contract manufacturing (CMO/CDMO) services. Its commercial portfolio includes key products such as Sodium Acetate Ringer's Injection, Venlafaxine Hydrochloride Extended-Release Capsules, Amisulpride Injection, and Tranexamic Acid Injection, targeting therapeutic areas like anesthesia, psychiatry, and anti-infectives. In August 2026, its parent company, Tibet Duorui Pharmaceutical, announced the divestment of 100% of Hubei Duorui's equity to Tibet Jiakang Shidai Technology Development for approximately 77.26 million RMB to optimize its business structure.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 湖北多瑞药业.